Path breaking solutions to large unmet needs in Antimicrobial resistance (AMR) and immuno-oncology. Making highly differentiated assets, affordable and accessible to all of humanity.

Bugworks Research Inc.

Celebrating a decade of innovation-driven research to address two major health issues afflicting humanity - #antimicrobialresistance and #cancer.
Bugworks is delighted to present a visual capsule of our journey thus far.

https://lnkd.in/duEiCizG

#amr #drugresistance #superbugs #drugdiscovery #drugdevelopment #innovation #cancer #immunooncology
#tumourmicroenvironment #affordability #accessibility
#translationalresearch #healthcare

📣 Bugworks has recently been featured in the Times of India, highlighting the global impact of antimicrobial resistance (AMR) and the innovative research conducted in India to combat this global pandemic. We are grateful to the Times of India for bringing attention to this critical issue and the groundbreaking work being done to combat it.

#antimicrobialresistance #AMR #innovation #antibioticresistance 
https://lnkd.in/ghf3wp5X

Bugworks is at the forefront of inventing differentiated, affordable and accessible solutions to tackle two significant global health challenges.

1. Novel antibiotics to address untreatable superbugs.
2. Novel solutions for hard-to-treat solid cell tumours.

Anand Anandkumar Santanu Datta Bala Subramanian Shahul Hameed P Vasan Sambandamurthy Leela Maitreyi Harish Kaushik Kotakonda, PhD 
UTEC - The University of Tokyo Edge Capital Partners 3one4 Capital Lightrock India Global Antibiotic R&D Partnership (GARDP) Centre for Cellular and Molecular Platforms (C-CAMP) Global Brain Corporation CARB-X 
#antimicrobialresistance #antimicrobialstewardship #immunooncology #oncology #targetedtherapy

✨The first baby steps into the daunting field of cancer ✨

We are thrilled to share that our team is presenting a poster at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023
🌍

📍 Location: Geneva, Switzerland
🔍 Poster Title: "Discovery of best-in-class dual-acting A2AR/A2BR antagonists that are efficacious in high adenosine tumor microenvironment"


https://lnkd.in/gqHCcqhJ

📣  Raising Awareness on Antimicrobial Resistance (AMR): Our Latest Article by Dr Vasanthi Ramachandran is Live! 💊

This AMR Awareness Week, we delve into the pressing need for innovation in antibiotics research and development. 💡 
🔗https://lnkd.in/g_Nr2-zd 

Let's work together to promote change, initiate discussions, and drive advancements that will ensure the development of effective treatments for the benefit of future generations.

 #AMRAwareness #InnovationInHealthcare #AntibioticsResearch #HealthForAll #InvestInHealthcareInnovation #antimicrobialresistance #antimicrobialstewardship

🏆 Celebrating: Bugworks Research India Pvt. Ltd. Wins an Award for Patent Portfolio in the Startup Segment! 🏆

Bugworks Research India Pvt. Ltd. won the runner-up award for Patents Portfolio in the Startup segment at the “CII Industrial IP Awards 2023”. We are greatly encouraged by the recognition and will strive to bring forth valuable, affordable and accessible solutions to combat AMR and Cancer worldwide.” 
 
Pic (L to R): Mr Vipin Sondhi, Chairman CII; Ms Pratibha Singh, Justice High Court, Delhi; Dr R. A. Mashelkar, former DG, CSIR & Chairman, Grand Jury CII IP Awards 2023; Dr V. Balasubramanian, COO, Bugworks Research India Pvt. Ltd. and Mr R. Saha, Senior Advisor, CII
 
#cii #ciipr #AwardWinners #ProudMoment #CompanyAchievement #InnovationInBusiness #Bugworks

Dr Anand Anandkumar, Our CEO, is set to grace the virtual stage as a speaker in an upcoming webinar!

📅 Date and Time: 21 November 2023, 5:30-7 PM IST
🖥️ Webinar Title: Rejuvenating The Global Antibiotic Innovation Ecosystem: The Way Forward

Let's unite for an enriching session that promises inspiration and strategic wisdom.

The World Anti-Microbial Resistance Congress is coming up! Our CEO, Dr. Anand Anandkumar, will discuss the importance of the LMICs in finding solutions to the AMR. We hope to see many of you there!

We’re delighted to announce that Bugworks Research Inc. and Global Antibiotic R&D Partnership (GARDP) are joining forces to accelerate the development of a novel antibiotic to treat serious bacterial infections. 

"We are thrilled to strengthen our ongoing partnership with GARDP to accelerate the clinical development of BWC0977 and deliver a truly differentiated broad-spectrum drug that can tackle the toughest drug-resistant superbugs."

This compound aims to treat patients with serious bacterial infections in critical care and community settings. 

Read the announcement: https://lnkd.in/di5gZM6W

#AMR #antibioticresistance #antimicrobialresistance #researchanddevelopment #drugdevelopment

We are delighted a proud that our CEO Dr. Anand Anandkumar has been awarded the “Entrepreneur of the Year 2021-22” by BioSpectrum India 

#entrepreneurship #AMR #antimicrobialresistance #leadership #awardsforexcellence #ceo

A competitor based in Malaysia, focusing on similar biotechnology and antibiotic-resistant bacterial infection treatments.

bugworks.com.my

An organization specializing in immunopharmacology, with a focus on developing therapeutics for various diseases.

guidetoimmunopharmacology.org

A biotechnology firm involved in the development and commercialization of novel therapeutics for antibiotic-resistant bacterial infections.

Prokaryotics

A company focused on developing novel treatments for multidrug-resistant bacterial infections.

Spero Therapeutics

A biopharmaceutical company specializing in the development of antibiotics for serious and life-threatening bacterial infections.

Tetraphase

Bugworks Research Inc. is a clinical stage biopharmaceutical company focused on developing novel therapies against infectious diseases and cancer. The company is dedicated to addressing the global health challenges posed by antimicrobial resistance (AMR) and cancer through innovative solutions.

news impact assignment basic	general	Mar 8, 2024 1:52 AM	bab856cb
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 1:52 AM	b85e14b2
company summary	general
signals	general	Mar 8, 2024 1:52 AM	e9dbf10c
crunchbase trigger	general	Nov 12, 2024 12:52 PM	249341c0
crunchbase profile	general
li profile	general	Mar 8, 2024 1:52 AM	da4235f7
translate crunchbase fundingrounds	general
peers	general	Mar 8, 2024 1:52 AM	952bf05b
news basic	general	Mar 8, 2024 1:52 AM	94550374
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:BUGWORKSRESEARCH

Bugworks Research Inc.